Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
66.7M
-
Number of holders
-
98
-
Total 13F shares, excl. options
-
20.7M
-
Shares change
-
+10.5M
-
Total reported value, excl. options
-
$48.4M
-
Value change
-
+$25.4M
-
Put/Call ratio
-
0.1
-
Number of buys
-
46
-
Number of sells
-
-54
-
Price
-
$2.34
Significant Holders of INOVIO PHARMACEUTICALS, INC. - Common Stock (INO) as of Q3 2025
132 filings reported holding INO - INOVIO PHARMACEUTICALS, INC. - Common Stock as of Q3 2025.
INOVIO PHARMACEUTICALS, INC. - Common Stock (INO) has 98 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 20.7M shares
of 66.7M outstanding shares and own 31.04% of the company stock.
Largest 10 shareholders include ADAGE CAPITAL PARTNERS GP, L.L.C. (3.43M shares), JANUS HENDERSON GROUP PLC (3.27M shares), VANGUARD GROUP INC (2.71M shares), Boxer Capital Management, LLC (2.3M shares), MILLENNIUM MANAGEMENT LLC (1.97M shares), RENAISSANCE TECHNOLOGIES LLC (816K shares), D. E. Shaw & Co., Inc. (807K shares), MORGAN STANLEY (787K shares), BANK OF AMERICA CORP /DE/ (636K shares), and GEODE CAPITAL MANAGEMENT, LLC (547K shares).
This table shows the top 98 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.